Associations of disease activity and treatments with mortality in men with rheumatoid arthritis: Results from the VARA registry

Ted R. Mikuls, Brian T. Fay, Kaleb Michaud, Harlan Sayles, Geoffrey M. Thiele, Liron Caplan, Dannette Johnson, John S. Richards, Gail S. Kerr, Grant W. Cannon, Andreas Reimold

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Objectives: To examine the all-cause mortality rate and factors associated with mortality in US veteran men with RA. Methods: Men with RA were enrolled and followed until death or censoring. Vital status was ascertained through systematic record review and standardized mortality ratios (SMRs) were calculated using US life tables for men. Multivariate Cox proportional hazards regression was used to examine the independent associations of patient factors including socio-demographics, comorbidity, measures of RA disease activity/severity and medication use with mortality. Measures of RA disease activity and medications were examined as time-varying factors. Results: A total of 138 deaths were observed during 2314 patient-years of follow-up (n = 1015 patients), corresponding to a crude morality rate of 5.9 deaths per 100 patient-years (95% CI 5.0, 7.0) and an SMR of 2.1 (95% CI 1.8, 2.5). After multivariate adjustment, factors independently associated with higher mortality risk in men with RA included older age, Caucasian race, low body weight, an increased frequency of rheumatology visits, higher ESR and RF concentrations, increased DAS28, subcutaneous nodules and prednisone use. In contrast, MTX use [hazard ratio (HR) 0.63; 95% CI 0.42, 0.96] was associated with ~40% lower mortality risk. Conclusion: Mortality rates among US male veterans with RA are more than twice those of age-matched men in the general population. These results suggest that optimizing disease control, particularly with regimens that include MTX and minimize glucocorticoid exposure, could improve long-term survival in this population.

Original languageEnglish (US)
Pages (from-to)101-109
Number of pages9
JournalRheumatology
Volume50
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Registries
Rheumatoid Arthritis
Mortality
Therapeutics
Veterans
Social Adjustment
Life Tables
Rheumatology
Prednisone
Glucocorticoids
Population
Comorbidity
Body Weight
Demography
Survival

Keywords

  • Glucocorticoids
  • Men
  • Mortality
  • MTX
  • Rheumatoid arthritis
  • US veterans

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Cite this

Associations of disease activity and treatments with mortality in men with rheumatoid arthritis : Results from the VARA registry. / Mikuls, Ted R.; Fay, Brian T.; Michaud, Kaleb; Sayles, Harlan; Thiele, Geoffrey M.; Caplan, Liron; Johnson, Dannette; Richards, John S.; Kerr, Gail S.; Cannon, Grant W.; Reimold, Andreas.

In: Rheumatology, Vol. 50, No. 1, 01.2011, p. 101-109.

Research output: Contribution to journalArticle

Mikuls, TR, Fay, BT, Michaud, K, Sayles, H, Thiele, GM, Caplan, L, Johnson, D, Richards, JS, Kerr, GS, Cannon, GW & Reimold, A 2011, 'Associations of disease activity and treatments with mortality in men with rheumatoid arthritis: Results from the VARA registry', Rheumatology, vol. 50, no. 1, pp. 101-109. https://doi.org/10.1093/rheumatology/keq232
Mikuls, Ted R. ; Fay, Brian T. ; Michaud, Kaleb ; Sayles, Harlan ; Thiele, Geoffrey M. ; Caplan, Liron ; Johnson, Dannette ; Richards, John S. ; Kerr, Gail S. ; Cannon, Grant W. ; Reimold, Andreas. / Associations of disease activity and treatments with mortality in men with rheumatoid arthritis : Results from the VARA registry. In: Rheumatology. 2011 ; Vol. 50, No. 1. pp. 101-109.
@article{dccd50a5ae604749b30e9b6f44d7c557,
title = "Associations of disease activity and treatments with mortality in men with rheumatoid arthritis: Results from the VARA registry",
abstract = "Objectives: To examine the all-cause mortality rate and factors associated with mortality in US veteran men with RA. Methods: Men with RA were enrolled and followed until death or censoring. Vital status was ascertained through systematic record review and standardized mortality ratios (SMRs) were calculated using US life tables for men. Multivariate Cox proportional hazards regression was used to examine the independent associations of patient factors including socio-demographics, comorbidity, measures of RA disease activity/severity and medication use with mortality. Measures of RA disease activity and medications were examined as time-varying factors. Results: A total of 138 deaths were observed during 2314 patient-years of follow-up (n = 1015 patients), corresponding to a crude morality rate of 5.9 deaths per 100 patient-years (95{\%} CI 5.0, 7.0) and an SMR of 2.1 (95{\%} CI 1.8, 2.5). After multivariate adjustment, factors independently associated with higher mortality risk in men with RA included older age, Caucasian race, low body weight, an increased frequency of rheumatology visits, higher ESR and RF concentrations, increased DAS28, subcutaneous nodules and prednisone use. In contrast, MTX use [hazard ratio (HR) 0.63; 95{\%} CI 0.42, 0.96] was associated with ~40{\%} lower mortality risk. Conclusion: Mortality rates among US male veterans with RA are more than twice those of age-matched men in the general population. These results suggest that optimizing disease control, particularly with regimens that include MTX and minimize glucocorticoid exposure, could improve long-term survival in this population.",
keywords = "Glucocorticoids, Men, Mortality, MTX, Rheumatoid arthritis, US veterans",
author = "Mikuls, {Ted R.} and Fay, {Brian T.} and Kaleb Michaud and Harlan Sayles and Thiele, {Geoffrey M.} and Liron Caplan and Dannette Johnson and Richards, {John S.} and Kerr, {Gail S.} and Cannon, {Grant W.} and Andreas Reimold",
year = "2011",
month = "1",
doi = "10.1093/rheumatology/keq232",
language = "English (US)",
volume = "50",
pages = "101--109",
journal = "Rheumatology (United Kingdom)",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Associations of disease activity and treatments with mortality in men with rheumatoid arthritis

T2 - Results from the VARA registry

AU - Mikuls, Ted R.

AU - Fay, Brian T.

AU - Michaud, Kaleb

AU - Sayles, Harlan

AU - Thiele, Geoffrey M.

AU - Caplan, Liron

AU - Johnson, Dannette

AU - Richards, John S.

AU - Kerr, Gail S.

AU - Cannon, Grant W.

AU - Reimold, Andreas

PY - 2011/1

Y1 - 2011/1

N2 - Objectives: To examine the all-cause mortality rate and factors associated with mortality in US veteran men with RA. Methods: Men with RA were enrolled and followed until death or censoring. Vital status was ascertained through systematic record review and standardized mortality ratios (SMRs) were calculated using US life tables for men. Multivariate Cox proportional hazards regression was used to examine the independent associations of patient factors including socio-demographics, comorbidity, measures of RA disease activity/severity and medication use with mortality. Measures of RA disease activity and medications were examined as time-varying factors. Results: A total of 138 deaths were observed during 2314 patient-years of follow-up (n = 1015 patients), corresponding to a crude morality rate of 5.9 deaths per 100 patient-years (95% CI 5.0, 7.0) and an SMR of 2.1 (95% CI 1.8, 2.5). After multivariate adjustment, factors independently associated with higher mortality risk in men with RA included older age, Caucasian race, low body weight, an increased frequency of rheumatology visits, higher ESR and RF concentrations, increased DAS28, subcutaneous nodules and prednisone use. In contrast, MTX use [hazard ratio (HR) 0.63; 95% CI 0.42, 0.96] was associated with ~40% lower mortality risk. Conclusion: Mortality rates among US male veterans with RA are more than twice those of age-matched men in the general population. These results suggest that optimizing disease control, particularly with regimens that include MTX and minimize glucocorticoid exposure, could improve long-term survival in this population.

AB - Objectives: To examine the all-cause mortality rate and factors associated with mortality in US veteran men with RA. Methods: Men with RA were enrolled and followed until death or censoring. Vital status was ascertained through systematic record review and standardized mortality ratios (SMRs) were calculated using US life tables for men. Multivariate Cox proportional hazards regression was used to examine the independent associations of patient factors including socio-demographics, comorbidity, measures of RA disease activity/severity and medication use with mortality. Measures of RA disease activity and medications were examined as time-varying factors. Results: A total of 138 deaths were observed during 2314 patient-years of follow-up (n = 1015 patients), corresponding to a crude morality rate of 5.9 deaths per 100 patient-years (95% CI 5.0, 7.0) and an SMR of 2.1 (95% CI 1.8, 2.5). After multivariate adjustment, factors independently associated with higher mortality risk in men with RA included older age, Caucasian race, low body weight, an increased frequency of rheumatology visits, higher ESR and RF concentrations, increased DAS28, subcutaneous nodules and prednisone use. In contrast, MTX use [hazard ratio (HR) 0.63; 95% CI 0.42, 0.96] was associated with ~40% lower mortality risk. Conclusion: Mortality rates among US male veterans with RA are more than twice those of age-matched men in the general population. These results suggest that optimizing disease control, particularly with regimens that include MTX and minimize glucocorticoid exposure, could improve long-term survival in this population.

KW - Glucocorticoids

KW - Men

KW - Mortality

KW - MTX

KW - Rheumatoid arthritis

KW - US veterans

UR - http://www.scopus.com/inward/record.url?scp=79951704870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951704870&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/keq232

DO - 10.1093/rheumatology/keq232

M3 - Article

C2 - 20659916

AN - SCOPUS:79951704870

VL - 50

SP - 101

EP - 109

JO - Rheumatology (United Kingdom)

JF - Rheumatology (United Kingdom)

SN - 1462-0324

IS - 1

ER -